Auxilium Teams with MBI for Life Sciences Growth
Central Massachusetts is experiencing unprecedented growth in the biotechnology sector, with Worcester emerging as a premier destination for life sciences innovation. Auxilium and Massachusetts Biomedical Initiatives (MBI) have launched a groundbreaking joint accelerator program designed to attract and nurture the next generation of biotech startups. This strategic partnership represents a significant milestone in establishing Worcester as a thriving biomanufacturing hub capable of competing with traditional innovation centers.
The three-month accelerator cohort offers comprehensive support to emerging healthcare and life sciences companies across multiple subsectors. Selected startups will receive substantial resources including a $250,000 capital investment, mentorship from experienced industry leaders, access to state-of-the-art laboratory facilities, sector-specific workshops, and complimentary workspace in downtown Worcester. This robust support system aims to accelerate company growth during critical early development stages.
Strategic Partnership Combines Expertise and Resources
The collaboration leverages MBI’s 40-year legacy as the Commonwealth’s longest-running nonprofit life sciences incubator with Auxilium’s modern accelerator platform and extensive founder coaching capabilities. MBI has successfully incubated over 188 companies since 2000, creating more than 1,800 jobs and helping startups raise over $1.4 billion in capital. This proven track record, combined with Auxilium’s fresh approach to entrepreneurial support, creates a powerful ecosystem for biotech innovation.
Auxilium executive director Zak Dutton emphasized the strategic importance of this partnership, noting that aligning with established organizations like MBI amplifies impact across Worcester’s life sciences sector. The program provides hands-on, sector-specific support embedded within Worcester’s rapidly expanding biotech ecosystem, offering startups direct access to regional networks and resources.
Comprehensive Support for Diverse Life Sciences Subsectors
The accelerator welcomes companies across numerous life sciences domains including digital health, medical technology, diagnostics, medical devices, AI-enabled healthcare solutions, and advanced life science tools. This broad sectoral approach reflects the diverse innovation landscape in biopharmaceuticals and ensures the program can support various technological approaches to healthcare advancement.
Program participants must operate on-site in Worcester throughout the three-month duration, working from Auxilium’s downtown offices while accessing MBI’s specialized laboratory and incubation facilities. This physical presence requirement fosters collaboration, networking, and deep integration into Central Massachusetts’ biotech community. The cohort concludes with a public pitch and demonstration event where founders present to investors, partners, and ecosystem leaders.
Worcester’s Emergence as National Biotech Leader
Central Massachusetts has rapidly transformed into one of America’s fastest-growing life sciences destinations. In 2025, Worcester achieved remarkable recognition by ranking among the top 25 nationally in three categories within the CBRE U.S. Life Sciences Talent and Trends report. Additionally, CoworkingCafe named Worcester among the top 10 mid-sized metros for STEM jobs, validating the region’s growing reputation as an innovation powerhouse.
The Commonwealth of Massachusetts recently announced a $5.2 million investment to establish the Central Massachusetts BioHub, led by Worcester Polytechnic Institute in partnership with MBI and more than 30 regional organizations. This substantial public investment demonstrates governmental commitment to developing Worcester’s biomanufacturing capabilities and competitive positioning against established biotech centers.
Application Timeline and Program Details
Applications for the Auxilium-MBI life sciences accelerator cohort opened on February 11, 2026, with submissions due by April 11. Final company selections will be announced on May 1, 2026, and the program officially launches on June 8, 2026. Interested founders can find additional information and application details at auxiliumworcester.com/auxilium-mbi-lifesciences-accelerator.
MBI President and CEO Jon Weaver characterized the program as an open invitation to innovators nationwide seeking to build their companies in a region deeply committed to entrepreneurial success. The cohort represents more than traditional acceleration—it offers emerging companies across the country an opportunity to establish operations where bioinnovation’s future is rapidly materializing.
This joint accelerator program positions Worcester strategically within the broader Massachusetts life sciences ecosystem, creating pathways for startup success while strengthening Central Massachusetts’ economic development and innovation capacity for years to come.
